---
schema_version: "secwatch.filing_event.v1"
accession: "0001831283-23-000124"
form_type: "8-K"
ticker: "LIANY"
cik: "0001831283"
company_name: "LianBio"
filed_at: "2023-11-13T23:59:59+00:00"
generated_at: "2026-06-08T05:25:05.431560+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# LianBio Q3 net loss $24M, inks $350M BMS mavacamten deal, strategic review ongoing

## Summary
- Net loss of $24.0M in Q3 2023 vs $21.9M loss in Q3 2022; cash $252.2M as of Sep 30, 2023.
- Entered agreement with BMS for mavacamten rights in China and other Asian markets for $350M total consideration.
- Phase 3 TP-03 for Demodex blepharitis: mite eradication significant (p<0.001), collarette cure not significant (p=0.15); plans NDA filing.
- Board initiated comprehensive strategic review in October 2023; update expected first half 2024.

## SEC filing metadata
- accession: 0001831283-23-000124
- form_type: 8-K
- ticker: LIANY
- cik: 0001831283
- company_name: LianBio
- filed_at: 2023-11-13T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1831283/000183128323000124/0001831283-23-000124-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1831283/000183128323000124/lian-20231113.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001831283-23-000124
- JSON: https://secwatch.observer/filing/0001831283-23-000124.json
- Plain text: https://secwatch.observer/filing/0001831283-23-000124.txt

## Key facts
- Earnings Releases
  LianBio reported the third quarter ended September 30, 2023 results: net income Net loss was $24.0 million for the third quarter of 2023.
  - Period: the third quarter ended September 30, 2023
  - Net income: Net loss was $24.0 million for the third quarter of 2023
  - Result: reported results
  source text: LianBio (Nasdaq: LIAN), a biotechnology company dedicated to bringing innovative medicines to patients in China and other major Asian markets, today reported financial results for the third quarter ended September 30, 2023.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1831283/000183128323000124/0001831283-23-000124-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.